Barr Is Latest Generic Firm To Take On FDA’s Patent-Based Exclusivity Policy
This article was originally published in The Tan Sheet
Executive Summary
Barr's lawsuit over 180-day generic marketing rights for Sanofi-Aventis' Allegra-D marks the most recent legal challenge to FDA's patent-based approach to awarding exclusivity
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning